Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen

Vaccine

Volumn 27, Issue 18, 2009, Pages 2453-2468

  Mealey, Robert H ^a   Leib, Steven R ^a   Littke, Matt H ^a   Wagner, Bettina ^b   Horohov, David W ^c   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Cornell University ^*  (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

CTL vaccine; EIAV; Gag DNA prime vaccinia vector boost; IL 2 IgG fusion; Lentivirus enhancement; Regulatory T cells

Indexed keywords

DNA VACCINE; GAG PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PROTEIN P15; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; EQUINE INFECTIOUS ANEMIA VIRUS; LENTIVIRINAE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; VIREMIA; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; GENETIC VECTORS; HORSES; IMMUNOGLOBULIN G; INFECTIOUS ANEMIA VIRUS, EQUINE; INTERLEUKIN-2; PLASMIDS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VACCINIA VIRUS; VIRAL LOAD; VIRAL VACCINES;

EID: 62749195480     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.048     Document Type: Article

References (103)

1. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5 (1999) 204-210
2. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 76 (2002) 2123-2130
3. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73 (1999) 4009-4018
4. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 (2000) 207-210
5. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 (1994) 6103-6110
6. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
7. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 69 (1995) 5838-5842
8. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S., et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses 15 (1999) 1219-1228
9. Klein M.R., Van Baalen C.A., Holwerda A.M., Kerkhof Garde S.R., Bende R.J., Keet I.P., et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181 (1995) 1365-1372
10. Kuroda M.J., Schmitz J.E., Charini W.A., Nickerson C.E., Lifton M.A., Lord C.I., et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 162 (1999) 5127-5133
11. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 (1999) 991-998
12. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
13. HIV vaccine failure prompts Merck to halt trial. Nature 2007;449:390.
14. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 318 (2007) 1048-1049
15. Self SG, Buchbinder S, McElrath MJ, Casimiro DR. HIV Vaccine Trials Network; 2007. http://www.hvtn.org/science/1107.html.
16. Sekaly R.P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 205 (2008) 7-12
17. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., and Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14 (2008) 617-621
18. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
19. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 (2005) 15547-15555
20. McDermott A.B., O'Connor D.H., Fuenger S., Piaskowski S., Martin S., Loffredo J., et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol 79 (2005) 15556-15566
21. McGuire T.C., Crawford T.B., and Henson J.B. Immunofluorescent localization of equine infectious anemia virus in tissue. Am J Pathol 62 (1971) 283-294
22. Montelaro R.C., Ball J.M., and Rushlow K.E. Equine retroviruses. In: Levy J.A. (Ed). The Retroviridae vol. 2 (1993), Plenum Press, New York 257-360
23. Oaks J.L., McGuire T.C., Ulibarri C., and Crawford T.B. Equine infectious anemia virus is found in tissue macrophages during subclinical infection. J Virol 72 (1998) 7263-7269
24. Cheevers W.P., and McGuire T.C. Equine infectious anemia virus: immunopathogenesis and persistence. Rev Infect Dis 7 (1985) 83-88
25. McGuire T.C., O'Rourke K.I., and Perryman L.E. Immunopathogenesis of equine infectious anemia lentivirus disease. Dev Biol Stand 72 (1990) 31-37
26. Mealey R.H., Fraser D.G., Oaks J.L., Cantor G.H., and McGuire T.C. Immune reconstitution prevents continuous equine infectious anemia virus replication in an arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses. Clin Immunol 101 (2001) 237-247
27. Perryman L.E., O'Rourke K.I., and McGuire T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J Virol 62 (1988) 3073-3076
28. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., and Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71 (1997) 3840-3852
29. McGuire T.C., Tumas D.B., Byrne K.M., Hines M.T., Leib S.R., Brassfield A.L., et al. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J Virol 68 (1994) 1459-1467
30. McGuire T.C., Fraser D.G., and Mealey R.H. Cytotoxic T lymphocytes and neutralizing antibody in the control of equine infectious anemia virus. Viral Immunol 15 (2002) 521-531
31. Mealey R.H., Sharif A., Ellis S.A., Littke M.H., Leib S.R., and McGuire T.C. Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 339 (2005) 110-126
32. Lonning S.M., Zhang W., Leib S.R., and McGuire T.C. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors. J Virol 73 (1999) 2762-2769
33. McGuire T.C., Leib S.R., Lonning S.M., Zhang W., Byrne K.M., and Mealey R.H. Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses. J Gen Virol 81 (2000) 2735-2739
34. Mealey R.H., Zhang B., Leib S.R., Littke M.H., and McGuire T.C. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313 (2003) 537-552
35. Zhang W., Lonning S.M., and McGuire T.C. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J Virol 72 (1998) 9612-9620
36. Chung C., Mealey R.H., and McGuire T.C. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins. Virology 327 (2004) 144-154
37. Buseyne F., McChesney M., Porrot F., Kovarik S., Guy B., and Riviere Y. Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol 67 (1993) 694-702
38. Goulder P.J., Tang Y., Pelton S.I., and Walker B.D. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J Virol 74 (2000) 5291-5299
39. Goulder P.J., Brander C., Annamalai K., Mngqundaniso N., Govender U., Tang Y., et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol 74 (2000) 5679-5690
40. Wilson C.C., Kalams S.A., Wilkes B.M., Ruhl D.J., Gao F., Hahn B.H., et al. Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. J Virol 71 (1997) 1256-1264
41. Chung C., Mealey R.H., and McGuire T.C. Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses. Virology 342 (2005) 228-239
42. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., and Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 (1992) 1938-1941
43. Wyand M.S., Manson K., Montefiori D.C., Lifson J.D., Johnson R.P., and Desrosiers R.C. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73 (1999) 8356-8363
44. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73 (1999) 4952-4961
45. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., et al. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77 (2003) 7244-7253
46. Shen T., Liang H., Tong X., Fan X., He X., Ma Y., et al. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 24 (2006) 738-749
47. Zhang X., Wang Y., Liang H., Wei L., Xiang W., Shen R., et al. Correlation between the induction of Th1 cytokines by an attenuated equine infectious anemia virus vaccine and protection against disease progression. J Gen Virol 88 (2007) 998-1004
48. Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., and Ruprecht R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267 (1995) 1820-1825
49. Hokey D.A., and Weiner D.B. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 28 (2006) 267-279
50. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci USA 97 (2000) 4192-4197
51. Landolfi N.F. A chimeric IL-2/Ig molecule possesses the functional activity of both proteins. J Immunol 146 (1991) 915-919
52. Barouch D.H., Truitt D.M., and Letvin N.L. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 22 (2004) 3092-3097
53. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (2000) 486-492
54. Mealey R.H., Stone D.M., Hines M.T., Alperin D.C., Littke M.H., Leib S.R., et al. Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route. Vaccine 25 (2007) 7582-7597
55. Paillot R., Ellis S.A., Daly J.M., Audonnet J.C., Minke J.M., Davis-Poynter N., et al. Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. Vaccine 24 (2006) 1490-1500
56. Bailey E. Identification and genetics of horse lymphocyte alloantigens. Immunogenetics 11 (1980) 499-506
57. Bailey E. Population studies on the ELA system in American standardbred and thoroughbred mares. Anim Blood Groups Biochem Genet 14 (1983) 201-211
58. Terasaki P.I., Bernoco D., Park M.S., Ozturk G., and Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol 69 (1978) 103-120
59. Chung C., Leib S.R., Fraser D.G., Ellis S.A., and McGuire T.C. Novel classical MHC class I alleles identified in horses by sequencing clones of reverse transcription-PCR products. Eur J Immunogenet 30 (2003) 387-396
60. McGuire T.C., Leib S.R., Mealey R.H., Fraser D.G., and Prieur D.J. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule. J Immunol 171 (2003) 1984-1993
61. Mealey R.H., Lee J.H., Leib S.R., Littke M.H., and McGuire T.C. A single amino acid difference within the alpha-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL. J Immunol 177 (2006) 7377-7390
62. Fraser D.G., Leib S.R., Zhang B.S., Mealey R.H., Brown W.C., and McGuire T.C. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge. Clin Diagn Lab Immunol 12 (2005) 983-993
63. Vandergrifft E.V., and Horohov D.W. Molecular cloning and expression of equine interleukin 2. Vet Immunol Immunopathol 39 (1993) 395-406
64. Overesch G., Wagner B., Radbruch A., and Leibold W. Organisation of the equine immunoglobulin constant heavy chain genes. II. Equine cgamma genes. Vet Immunol Immunopathol 66 (1998) 273-287
65. Mealey R.H., Littke M.H., Leib S.R., Davis W.C., and McGuire T.C. Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy. Vet Immunol Immunopathol 121 (2008) 8-22
66. McGuire T.C., O'Rourke K.I., Baszler T.V., Leib S.R., Brassfield A.L., and Davis W.C. Expression of functional protease and subviral particles by vaccinia virus containing equine infectious anaemia virus gag and 5' pol genes. J Gen Virol 75 (1994) 895-900
67. Blasco R., and Moss B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158 (1995) 157-162
68. Siliciano R.F., Keegan A.D., Dintzis R.Z., Dintzis H.M., and Shin H.S. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J Immunol 135 (1985) 906-914
69. Blanchard-Channell M., Moore P.F., and Stott J.L. Characterization of monoclonal antibodies specific for equine homologues of CD3 and CD5. Immunology 82 (1994) 548-554
70. Lunn D.P., Holmes M.A., Antczak D.F., Agerwal N., Baker J., Bendali-Ahcene S., et al. Report of the second equine leucocyte antigen workshop, Squaw valley, California, July 1995. Vet Immunol Immunopathol 62 (1998) 101-143
71. Kydd J., Antczak D.F., Allen W.R., Barbis D., Butcher G., Davis W., et al. Report of the first international workshop on equine leucocyte antigens, Cambridge, UK, July 1991. Vet Immunol Immunopathol 42 (1994) 3-60
72. Hammond S.A., Cook S.J., Falo Jr. L.D., Issel C.J., and Montelaro R.C. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 254 (1999) 37-49
73. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., and Montelaro R.C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245 (1998) 151-162
74. Sponseller B.A., Sparks W.O., Wannemuehler Y., Li Y., Antons A.K., Oaks J.L., et al. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease. Virology 363 (2007) 156-165
75. Motulsky H. Intuitive Biostatistics (1995), Oxford University Press, New York
76. Leroux C., Craigo J.K., Issel C.J., and Montelaro R.C. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75 (2001) 4570-4583
77. Dohmann K., Wagner B., Horohov D.W., and Leibold W. Expression and characterisation of equine interleukin 2 and interleukin 4. Vet Immunol Immunopathol 77 (2000) 243-256
78. Lunn D.P., Holmes M.A., Schram B., and Duffus W.P. Monoclonal antibodies specific for equine IgG sub-isotypes including an antibody which recognizes B lymphocytes. Vet Immunol Immunopathol 47 (1995) 239-251
79. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., and Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24 (2006) 1180-1190
80. Mair T.S., Batten E.H., Stokes C.R., and Bourne F.J. The histological features of the immune system of the equine respiratory tract. J Comp Pathol 97 (1987) 575-586
81. Mair T.S., Batten E.H., Stokes C.R., and Bourne F.J. The distribution of mucosal lymphoid nodules in the equine respiratory tract. J Comp Pathol 99 (1988) 159-168
82. Kumar P., Timoney J.F., and Sheoran A.S. M cells and associated lymphoid tissue of the equine nasopharyngeal tonsil. Equine Vet J 33 (2001) 224-230
83. Kim T.W., Chung H., Kwon I.C., Sung H.C., Kang T.H., Han H.D., et al. Induction of immunity against hepatitis B virus surface antigen by intranasal DNA vaccination using a cationic emulsion as a mucosal gene carrier. Mol Cells 22 (2006) 175-181
84. Wang X., Hone D.M., Haddad A., Shata M.T., and Pascual D.W. M cell DNA vaccination for CTL immunity to HIV. J Immunol 171 (2003) 4717-4725
85. Aggarwal P., Kumar S., Vajpayee M., and Seth P. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct. Viral Immunol 18 (2005) 649-656
86. Xin K.Q., Hamajima K., Sasaki S., Honsho A., Tsuji T., Ishii N., et al. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 94 (1998) 438-444
87. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 161 (1998) 1875-1882
88. Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Cook S.J., Raabe M.L., et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199 (1994) 247-251
89. McElrath M.J., Corey L., Greenberg P.D., Matthews T.J., Montefiori D.C., Rowen L., et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA 93 (1996) 3972-3977
90. Hammond S.A., Raabe M.L., Issel C.J., and Montelaro R.C. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262 (1999) 416-430
91. Raabe M.L., Issel C.J., and Montelaro R.C. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology 259 (1999) 416-427
92. Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1 (1988) 790-794
93. Robinson Jr. W.E., Montefiori D.C., Mitchell W.M., Prince A.M., Alter H.J., Dreesman G.R., et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci USA 86 (1989) 4710-4714
94. Montefiori D.C., Robinson Jr. W.E., Hirsch V.M., Modliszewski A., Mitchell W.M., and Johnson P.R. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol 64 (1990) 113-119
95. Takeda A., Tuazon C.U., and Ennis F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 (1988) 580-583
96. Klonjkowski B., Klein D., Galea S., Gavard F., Monteil M., Duarte L., et al. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS. Vaccine 27 (2009) 928-939
97. Li S., Gowans E.J., Chougnet C., Plebanski M., and Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 82 (2008) 21-30
98. Kasow K.A., Chen X., Knowles J., Wichlan D., Handgretinger R., and Riberdy J.M. Human CD4 + CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+. J Immunol 172 (2004) 6123-6128
99. Velilla P.A., Shata M.T., Lages C.S., Ying J., Fichtenbaum C.J., and Chougnet C. Effect of low-dose IL-2 immunotherapy on frequency and phenotype of regulatory T cells and NK cells in HIV/HCV-coinfected patients. AIDS Res Hum Retroviruses 24 (2008) 52-61
100. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188 (1998) 2205-2213
101. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10 (2009) 29-37
102. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007) 670-684
103. Streeck H., Brumme Z.L., Anastario M., Cohen K.W., Jolin J.S., Meier A., et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 5 (2008) e100